clinical_trials
STAT+: Vertex kidney disease drug scrutinized for infection risk
Confidence88·multiple reportsImportance90NP-EVT-20261029-B4D5189
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
Read the original at the primary source
STAT+: Vertex kidney disease drug scrutinized for infection risk
Adam Feuerstein · 10/29/2026, 1:25:01 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —